Screenshot 2020-03-04 17.26.59.png

Novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet need

We are a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-β, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone.

molecule.1.jpg

Our Leads

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from rare hematologic and musculoskeletal disorders with high unmet medical need.

 

“The Keros team has a deep understanding of the biology relevant to the role of members of the TGF-β family of proteins in the development of blood cells, muscle and bone, and we have leveraged that knowledge to advance two product candidates into Phase 1 clinical trials”

— Jasbir S. Seehra, Ph.D., President and CEO of Keros